Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.

摘要: Cancer is a genetic disease and this concept now widely exploited by both scientists clinicians to design new targeted molecules. Indeed many data have already allowed us ameliorate not only our knowledge about cancer onset, but also patients treatment. Correlation between mutations in alleles drug response key point identify drugs that match the profile of each individual tumors. On other hand, experience derived from inhibition tyrosine kinase receptors has pointed out treatment really successful small subset The latter are eventually addicted those alterations which responsible for activation continued expression their signalling. Overall these observations provide strong rationale molecular-based diagnosis selection therapies. This review analyses current state art molecularly-tailored pharmacological approach lung cancer, one biggest killers among human solid Main relevance addressed lesions activating EGFR pathway transducers, focusing on role as markers response.